What Are Wall Street Analysts' Target Price for Cencora Stock?

Company Overview - Cencora, Inc. is a leading global pharmaceutical distribution and healthcare solutions company with a market cap of approximately $70.5 billion, connecting drug manufacturers with pharmacies, hospitals, and healthcare providers worldwide [1] Stock Performance - Cencora's stock has significantly outperformed the broader market, soaring 46.6% over the past 52 weeks compared to the S&P 500 Index's 15.6% gains [2] - The stock is up 7.6% in 2026, surpassing the index's 1.7% rise [2] - Cencora has also outperformed the VanEck Pharmaceutical ETF, which gained 22.9% over the past 52 weeks and 6.5% year-to-date [3] Financial Results - For fiscal 2026 first-quarter results, Cencora reported revenue of about $85.9 billion, up 5.5% year over year, with adjusted diluted EPS rising to $4.08, an increase of roughly 9% from the prior year [5] - Adjusted gross profit climbed to $3 billion, supported by strong volumes and favorable segment mix, while adjusted operating income grew nearly 12% to $1.1 billion [5] Earnings Expectations - Analysts expect Cencora to deliver an adjusted EPS of $17.57 for the current year ending in September, representing a 9.8% year-over-year increase [6] - The company has a strong earnings surprise history, surpassing bottom-line estimates in each of the past four quarters [6] Analyst Ratings - Among the 16 analysts covering Cencora stock, the consensus rating is a "Strong Buy," based on 14 "Strong Buys" and two "Holds" [6] - The bullish sentiment has increased from a month ago when there were 12 "Strong Buy" suggestions [7] - Evercore ISI recently lowered its price target on Cencora to $420 from $440 while maintaining an "Outperform" rating, indicating that the recent 8% selloff appears overdone [7]